Regeneron, Sanofi Arthritis Drug Fails Late-Stage Study in COVID-19 Patients Regeneron, Sanofi Arthritis Drug Fails Late-Stage Study in COVID-19 Patients
Regeneron Pharmaceuticals and Sanofi said on Thursday their rheumatoid arthritis drug Kevzara failed to meet the main goals of a late-stage study testing it in COVID-19 patients.Reuters Health Information
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Infectious Diseases News Source Type: news
More News: Arthritis | COVID-19 | Infectious Diseases | Intensive Care | Rheumatoid Arthritis | Rheumatology | Study